- Home
- XAIR
XAIR
Beyond Air Inc.
as 05-30-2025 4:00pm EST
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | GARDEN CITY |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $1.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.16 - $1.49 | Next Earning Date: | 06-17-2025 |
| Revenue: | $3,023,000 | Revenue Growth: | 338.75% |
| Revenue Growth (this year): | 244.61% | Revenue Growth (next year): | 258.76% |
Stock Insider Trading Activity of Beyond Air Inc. (XAIR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carey Robert | XAIR | Director | Mar 14 '25 | Buy | $0.25 | 1,000,000 | $250,050.00 | 4,066,864 |
Latest Beyond Air Inc. News
XAIR Breaking Stock News: Dive into XAIR Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast
GlobeNewswire
a month ago
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)
GlobeNewswire
a month ago
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
GlobeNewswire
a month ago
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board
GlobeNewswire
2 months ago
Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home
GlobeNewswire
2 months ago
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders
GlobeNewswire
2 months ago
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site
GlobeNewswire
2 months ago
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy
Compare XAIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XAIR Beyond Air Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.